Merck will evaluate Keytruda cancer combo therapy

Merck will collaborate with Syndax to evaluate the pairing of an anti-PD-1 therapy in Keytruda with HDAC inhibitor entinostat.

Bayer expands MIT/Harvard collaboration

The focus will now include cardiovascular disease.

Five things for pharma marketers to know: Tuesday, March 31

Five things for pharma marketers to know: Tuesday, March 31

Pfizer spent over $1 billion on ads last year; Monday's M&A activity accounted for about 25% of this year's total; Actavis is selling its Australian generics business

Teva will acquire Auspex to fill Copaxone patent hole

Teva will acquire Auspex to fill Copaxone patent hole

The drugmaker known for its massive presence in generics purchased Auspex Pharmaceuticals to bolster its growing specialty business.

Horizon makes $1.1-billion rare-disease push

Horizon makes $1.1-billion rare-disease push

Horizon Pharma's purchase of Hyperion Therapeutics will add two rare-disease drugs to its portfolio.

White House "superbug" plan has five-year goal

The White House's National Action Plan for Reducing Antibiotic-Resistant Bacteria proposal includes $1.2 billion in funding to reduce superbug infections and develop new diagnostics.

Medicare shelled out more than $4.7 billion on hep C last year

Key contributors to the total: Sovaldi, Harvoni and Olysio

Five things for pharma marketers to know: Monday, March 30

Five things for pharma marketers to know: Monday, March 30

UnitedHealth Group buys PBM Catamaran; Sanofi launches Toujeo; Teva acquires Auspex Pharmaceuticals

Five things for pharma marketers to know: Friday, March 27

Five things for pharma marketers to know: Friday, March 27

Novo announces it will resubmit Tresiba to the FDA; WHO urges Europe to share cost-effectiveness data; J&J and Google partner to develop robotic surgery system

Diabetes diagnoses jumped as a result of healthcare reform

Diabetes diagnoses jumped as a result of healthcare reform

Diagnoses spiked in states with expanded Medicaid programs. This may mean higher prescription rates, but research shows a lack of diagnoses also has a price.

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.

Email Newsletters